Achieving a Healthier and Sustainable Future for All - Policy Perspectives on Universal Health Coverage from the Innovative Biopharmaceutical Industry
Read More
Stepping up the Fight: Industry Collaboration to End HIV, Tuberculosis and Malaria
Now is the time to step up our fight against HIV, TB and malaria — we must do more, innovate more, and most importantly, partner more.
Read More
Thought Leader Series on Vaccines
In this special series on vaccines, IFPMA invites key opinion leaders to advance thinking and ideas on key issues that can drive efforts to allow the “miracle” of life-saving vaccines to reach all.
Read More
50 Years of Global Health Progress Report
This report traces global health progress over the past 50 years. It reviews some of the research-based biopharmaceutical industry’s major scientific advances, as well as acknowledging challenges the industry faces and areas of unfinished business.
Read more
New IFPMA Code of Practice 2019
New IFPMA Code of Practice will enter into force on 1st January 2019
New Code
Global Innovation Index Report 2019
This year’s report features a chapter titled “Reaching New Frontiers for Alzheimer’s through Research and Innovation”, penned by IFPMA President, CEO and Chair of Eli Lilly, David A. Ricks, along with Professor Brandy R. Matthews.
Read More
The Complex Journey of a Vaccine
The development of novel vaccines is a long endeavor. It takes usually between 10 to 15 years to develop a novel vaccine, as well as establishing its quality, safety and efficacy.
Read MoreIFPMA in Brief
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Tackling Global health challenges
The research-based biopharmaceutical industry is proud to be playing its part in the quest to find effective and sustainable solutions to today’s most pressing health concerns.
Read More
Boosting Innovation and Access
The research-based biopharmaceutical industry is thinking creatively about its innovation and business models to meet new challenges, and is working in collaboration with different players from the scientific community.
Read More
Strengthening Regulatory Systems
Patients everywhere should be treated with high quality medicines and vaccines. Science-based guidelines provide direction for the development, manufacture, and supply of medicines.
Read More
Building trust
The healthcare community and the public must be confident that research-based biopharmaceutical industry and their employees, wherever they operate, communicate and act in an ethical and professional manner.
Read More
Discovering medicines and Vaccines
Never have people lived longer and never have so many children been saved from dying in the first years of life. Medicines and vaccines extend and improve the quality of life for many people.
Read More
Our Resources
Stepping up the Fight: Industry Collaboration to End HIV, Tuberculosis and Malaria
Read More
IFPMA & IFPW Supply chain session 2016 Global Health Forum - long version
The session that took place at 2016 GHF ‘Shaping a sound supply chain ecosystem’ gathered speakers from BMS, IFPW Walgreens Boots Alliance, ICRC and WHO. Moderated by Scrip’s Sukaina Virji. To find out more about the complexities of the pharmaceutical supply chain, to hear what experts think are the essential...
Read More
IFPMA Welcomes Set-Up of New African Medicines Agency
Geneva, 25 May 2018 – To mark Africa Day, soon after African health ministers of 55-country African Union, all gathered at the 71st World Health Assembly, unanimously adopted a treaty to establish the African Medicines Agency, IFPMA seizes this momentum to welcome this important milestone. The new African Medicines Agency...
Read More
Greg Perry - IFPMA Moderated Panels @Pre-ICDRA 2018
Read More
IFPMA Statement at WHA72 12.1 agenda item Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits
Seasonal influenza virus sharing is already being negatively impacted by national implementation of the Nagoya Protocol in some countries. Several instances have been reported by the WHO Collaborating Centers where countries have delayed, or stopped altogether, the sharing of seasonal influenza virus samples on the grounds of conflict with local...
Read MoreJoin IFPMA
Our membership has three levels tailored to meet specific needs. Full Members have to be R&D-based pharmaceutical companies or national associations whose membership includes innovative pharmaceutical companies; Associate Members of R&D-based pharmaceutical companies and national associations whose permanent staff numbers are less than five, and Affiliate Members that are organizations, associations, companies and institutions who are supportive of the R&D-based
LEARN MOREOur Blog
Five questions to .... Dr. Angela Gichaga
As world leaders meet at the United Nations General Assembly to discuss the “Universal Health Coverage: Moving Together to Build a Healthier World” which aims to accelerate progress toward universal health coverage, Dr. Angela Nyambura Gichaga, Chief Executive Officer, the Financing Alliance for Health (FAH) explains how partnerships can help governments make the most of existing resources, increase domestic commitments, and identify new financing options...
Read More
Five questions to .... Paola Barbarino
Paola Barbarino, Chief Executive Officer at Alzheimer's Disease International (ADI), talks to IFPMA about changing attitudes and perceptions surrounding dementia and Alzheimer's. Is mental health getting enough attention in the UHC discussions and what are your hopes for the upcoming UN High Level Meeting on UHC? Following on from the High-Level Meeting on Non-Communicable Diseases in 2018, we were both heartened and frustrated. Heartened by...
Read More
The search for a dementia cure rests on helping innovators
This article was originally published in the Financial Times on August 6, 2019. The search for a dementia cure rests on helping innovators Governments must steer private funding towards difficult diseases Innovation can change the maths of Alzheimer’s disease. But to do that, governments need to change the maths for innovators. The estimated annual global cost of care for people with Alzheimer’s and other forms...
Read MoreLatest Tweets
